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Abstract
Background: The short form of the International Physical Activity Questionnaire (IPAQ-sf) is a validated questionnaire
used to assess physical activity (PA) in healthy adults and commonly used in both apparently healthy adults and cancer
patients. However, the IPAQ-sf has not been previously validated in cancer patients undergoing oncologic treatment.
The objective of the present study was to compare IPAQ-sf with objective measures of physical activity (PA) in cancer
patients undergoing chemotherapy.
Methods: The present study was part of a 12-month prospective individualized lifestyle intervention focusing on diet,
PA, stress management and smoking cessation in 100 cancer patients undergoing chemotherapy. During the first two
months of the lifestyle intervention, participants were wearing an activity monitor (SenseWear™ Armband (SWA)) for
five consecutive days while receiving chemotherapy before completing the IPAQ-sf. From SWA, Moderate-to-Vigorous
intensity PA (MVPA) in bouts ≥10 min was compared with self-reported MVPA from the IPAQ-sf. Analyses both
included and excluded walking in MVPA from the IPAQ-sf. Results were extrapolated to a wearing time of seven days.
Results: Sixty-six patients completed IPAQ-sf and wore the SWA over five days. Mean difference and limit of
agreement between the IPAQ-sf and SWA including walking was 662 (±1719) min.wk−1. When analyzing time spent
in the different intensity levels separately, IPAQ-sf reported significantly higher levels of moderate (602 min.wk−1,
p = 0.001) and vigorous (60 min.wk−1, p = 0.001) PA compared to SWA.
Conclusions: Cancer patients participating in a lifestyle intervention during chemotherapy reported 366 % higher
MVPA level from the past seven days using IPAQ-sf compared to objective measures. The IPAQ-sf appears insufficient
when assessing PA level in cancer patients undergoing oncologic treatment. Activity monitors or other objective tools
should alternatively be considered, when assessing PA in this population.
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Background
The number of new cancer cases is continuously rising
and is estimated to grow from 12.7 million new cases in
2008 to more than 22 million new cases worldwide in
2030 [1, 2]. Parallel to this increase, the possibilities for
surviving cancer has never been better with 32.6 million
cancer survivors worldwide in 2012 [3]. Many cancer
survivors are expected to return to normal and productive
lives following their diagnosis. However, cancer and its
treatments are often associated with long-term impair-
ment of physical, mental and psychosocial health and sur-
vivors are at risk of developing co-morbidities [4, 5].
Physical activity (PA) is recommended as a strategy both
during and after chemotherapy to manage treatment-
related symptoms, prevent early and late co-morbidities,
improve quality of life, increase the rate of chemotherapy
completion and possibly extend overall and disease-
specific survival in cancer patients [6–8]. Consequently,
the American Cancer Society has provided a set of general
PA recommendations for cancer patients and survivors.
Accordingly, cancer patients should avoid inactivity, try to
return to normal daily activities as soon as possible follow-
ing diagnosis, and follow the general PA guidelines for aer-
obic and strength exercise. This recommendation is >150
min of moderate PA per week combined with strength
training two days per week. Further, the importance of in-
dividualizing these PA recommendations to the patient’s
condition and preferences is pointed out, and it is empha-
sized that cancer patients may need to exercise at a lower
intensity and/or for a shorter duration during their treat-
ment [6]. These global PA recommendations are largely
based on self-reports of cancer patients’ PA levels [6].
The International Physical Activity Questionnaire
(IPAQ) is a validated questionnaire developed to moni-
tor self-reported PA levels in healthy adults [9], and the
most commonly used self-report tool of PA worldwide
[10, 11]. However, limitations of the IPAQ include its
length, low compliance and difficulties in completing the
questionnaire [12]. These difficulties may be of even
greater magnitude for cancer patients experiencing dis-
ease and treatment-related side-effects like fatigue, loss
of interest, and cognitive difficulties [13, 14] when
undergoing chemotherapy. A short form of the IPAQ
(IPAQ-sf ) is therefore preferred and previously used in
cancer patients [15], but has not been validated in can-
cer patients. Cancer is primarily a disease of the elderly
[16], which can make the use of the IPAQ-sf challenging
since the questionnaire is developed for adults aged
18–65 years [9]. Secondly, the IPAQ-sf defines moderate
PA as activities that make you breathe somewhat harder
than normal [17]. In this regard it is of major importance
to be aware of the fact that cancer patients undergoing
chemotherapy usually are fatigued, which may impair the
patients’ perceived level and intensity of PA. A validation
study of IPAQ-sf across 12 countries revealed large varia-
tions with respect to correlation between IPAQ and ob-
jective measures of PA by activity monitors [9]. Thus, it is
likely that the accuracy of the IPAQ varies when different
populations are assessed, dependent on the populations’
demographics, cultural backgrounds, physical fitness, level
of physical functioning and disease status [12, 18]. The ob-
jective of the present study was therefore to compare time
in Moderate-to-Vigorous intensity PA (MVPA) recorded
with the short form of the IPAQ with activity directly
quantified using SenseWear™ Armband (SWA) in cancer
patients receiving chemotherapy with curative or palliative
intent.
Methods
The present validation study is part of the I CAN-study
[19]; a 12-month prospective feasibility intervention with
the aim to increase population based adherence to
healthy lifestyle behaviors including diet, PA, mental
stress management and smoking cessation. The inter-
vention was delivered to 100 cancer patients undergoing
chemotherapy with curative or palliative intent through:
1) a grouped start-up course with patients and nearest
relatives, 2) an information binder with recommenda-
tions, recipes and tips on how to manage possible
disease and treatment-related symptoms themselves, and
3) monthly counseling with a lifestyle supervisor with
recommendations individualized to the patients’ abilities,
barriers and preferences. The study is described in detail
elsewhere [19].
Participants
All cancer patients receiving chemotherapy for all cancer
types, with either curative or palliative intent, at one on-
cology center in Kristiansand, Norway were considered
for study participation against the following inclusion
criteria: 1) age ≥ 18 years; 2) life expectancy ≥ 6 months;
3) Eastern Cooperative Oncology Group performance sta-
tus (ECOG) ≤ 2; and 4) able to speak and read Norwegian.
The only exclusion criterion was suspected anorexia
cachexia syndrome. The study was conducted according
to the guidelines of the Helsinki Declaration. The Regional
Committee for Medical and Health Research Ethics,
South-East approved the study (ref.no. 2012/1717/REK).
Written informed consent was obtained from all patients
before inclusion.
Procedures
Medical and demographic characteristics were collected
via self-report and medical records. These included date
of birth, height (collected by the physicians before start-
up of chemotherapy), tumor type (later categorized into
1 = breast cancer; 2 = colorectal cancer; 3 = prostate can-
cer; 4 = other cancer types), tumor stage (I-IV), ECOG
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(0–2), treatment intention (curative or palliative), marital
status, cigarette smoking status and education level.
Weight was measured to the nearest 0.5 kg (Mechanical
scale, Seca 761, Birmingham, United Kingdom) and body
mass index (BMI) was calculated by dividing weight (kg)
by height (m) squared. Self-reported PA was assessed
using the IPAQ-sf. Objective quantification of PA was
acquired via the SWA, either in conjunction with the
participants’ first or the second appointed visit in the I
CAN-study. The participants had undergone chemo-
therapy from five to twelve weeks at this time point.
Participants were instructed to wear the SWA for five
consecutive days; both including work week and week-
end days. Since the present study was part of a compre-
hensive lifestyle study, participants’ diet, mental stress,
cigarette smoking and quality of life were assessed in
addition to their PA level; a total of 59 questions.
Short form of the International Physical Activity
Questionnaire (IPAQ-sf)
The IPAQ-sf questionnaire assesses PA in bouts of ≥ 10
min as part of leisure time, domestic and gardening ac-
tivities, and work and transportation activities the past
seven days. PA is classified as either Vigorous PA (VPA),
Moderate PA (MPA) or as walking [17]. All walking was
included to MPA, as proposed by Craig et al. [9].
Additionally, MPA minus time spent on walking is pre-
sented. Total PA was defined as the sum of time in
MVPA.
SenseWear Armband
SenseWear™ Armband Pro3 and Mini (BodyMedia Inc.
Pittsburgh, PA) has been shown valid compared to indir-
ect calorimetry in cancer patients (underestimation of
daily energy expenditure by 9%, r = 0.68; p < 0.01) [20]
and doubly labeled water in healthy adults (underestima-
tion of daily energy expenditure by 5%, r = 0.81; p < 0.01)
[21]. The sensor array includes an accelerometer, heat
flux-sensor, galvanic skin response sensor, skin tem-
perature sensor and a near-body ambient temperature
sensor [21]. The SWA was worn on the triceps muscle
halfway between the acromion and olecranon processes of
the upper arm, as recommended by the manufacturer.
Participants were instructed to remove the SWA during
water-based activities, such as swimming or bathing, as
the monitor is not waterproof. Data were downloaded
with software developed by the manufacturer (SenseWear
Professional Research Software V.6.1 for Pro3 and V7.0 for
Mini, algorithm V.2.2.4) after entering necessary demo-
graphic characteristics (sex, age, height, weight, smoking
status).
The SWA was programmed to record PA in 1-min
epochs. The cut-points defined MPA as 3–6 METs and
VPA >6 METs in bouts ≥10 min. Total PA was defined
as the sum of MVPA in bouts of ≥10 min. Min.wk−1 from
the SWA for each participant was calculated by multipli-
cation of mean MVPA min.day−1 by seven. Complete mea-
surements required SWA wearing-time ≥19.2 h.day−1 on
at least one day.
Data analysis
Descriptive characteristics are presented as mean and
standard deviation (SD). The PA data are presented as
min.wk−1 in the present study. The mean difference
(IPAQ-sf minus SWA) ± 1.96 SD was calculated accord-
ing to Bland and Altman [22]. To test if the IPAQ-sf
overestimated PA compared to SWA, we applied a
Wilcoxon signed-rank test for the absolute values for
each activity monitor. Differences are presented as
means with 95 % Confidence Intervals (CI). Additionally,
the percentage discrepancy between IPAQ-sf and the
SWA was calculated for each individual within different
intensity categories. A linear regression with MVPA
from SWA as the independent variable and the differ-
ence between IPAQ-sf and SWA for MVPA as the
dependent variable was applied to test for systematic
over-reporting. Level of significance was set to 0.05.
Statistical analysis was performed with SPSS statistical
software version 22 (SPSS Inc., Chicago, IL, USA). A
post hoc power analysis using G*Power [23] yielded a
power of 0.99 to detect differences between means,
based on an effect size of 0.5.
Results
From the 100 I CAN participants, 16 participants
dropped out before enrolment in the present validation
study. The remaining 84 participants received a SWA
and completed the IPAQ-sf. Of these, 18 were elimi-
nated due to 1) SWA malfunction (n = 14) or 2) not
sufficient wearing-time of the SWA (n = 4). In total 66
participants had valid registrations on the SWA and
were included to the present validation study. There
were no significant differences in self-reported MVPA
between participants vs. non-participants at baseline
(p = 0.414). Participants wore the SWA for an average of
3.6 days and 23.7 h.day−1 of all valid days. Demographic,
medical and physical characteristics of the participants
(n = 66) and non-participants (n = 34) are presented in
Table 1.
Time in MPA, VPA and MVPA, including and excluding
walking
The mean differences and limits of agreements between
the IPAQ-sf and SWA from the Bland-Altman plots for
time in MVPA were 662 (1719) min.wk−1 and 203 (1070)
min.wk−1 with walking included and excluded in the
analyses, respectively (Fig. 1a and b). Figure 1c and d de-
picts the mean differences and limits of agreements
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between the IPAQ-sf and the SWA from the Bland-
Altman plots for time in MPA with walking included
and excluded from the analyses; 602 (1694) min.wk−1
and 143 (1009) min.wk−1, respectively. Furthermore,
Fig. 1 shows that several of the participants also under-
reported their PA compared to the SWA (plots under
the solid line). From the IPAQ-sf, 23 participants re-
ported VPA during the last week. The SWA only identi-
fied three participants conducting VPA during the same
seven-day period, and VPA is thus not depicted in a
Bland-Altman plot. Linear regression revealed no signifi-
cant systematic over-reporting; indicating those who had
Table 1 Characteristics of participants (n = 66) and non-participants (n = 34). Presented as frequencies and percentages in parenthesis
unless otherwise stated*
Participants Non-participants P-value
n = 66 (%) n = 34 (%)
Age, mean (SD)* 59 (11) 62 (12) .254
Height, mean (SD)* 169 (9) 172 (8) .111
Weight, mean (SD)* 72 (14) 78 (16) .085
BMI, mean (SD)* 25.2 (4.3) 26.1 (4.4) .335
Waist circumference, mean (SD)* 91 (12) 96 (13) .097
Sex
- Men 18 (28) 12 (35) .407
- Women 48 (72) 22 (65)
Marital status
- Married/living together 57 (86) 23 (68) .027
- Single/divorced/widowed 9 (14) 11 (32)
Education levela
- High school or less 34 (52) 13 (41) .279
- College/university 31 (48) 19 (59)
Cigarette smoking
- Smoker 8 (12) 5 (15) .716
- Non-smoker 58 (88) 29 (85)
ECOG
- 0 49 (74) 29 (85) .312
- 1 16 (24) 4 (12)
- 2 1 (2) 1 (3)
Treatment intention
- Curative 44 (67) 17 (50) .106
- Palliative 22 (33) 17 (50)
Tumor stage
- I 12 (18) 4 (12) .564
- II 14 (21) 7 (20)
- III 16 (24) 6 (18)
- IV 24 (37) 17 (50)
Diagnosis
- Breast cancer 35 (53) 11 (32) .036
- Colorectal cancer 22 (33) 10 (30)
- Prostate cancer 2 (3) 2 (6)
- Other 7 (11) 11 (32)
Self-reported moderate-to-Vigorous PA, mean (SD)* (min.wk−1) 833 (989) 675 (694) .414
aMissing value
*standard deviation
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the highest levels of PA did not significantly over-report
their PA levels the most. When comparing the min.wk−1
differences between IPAQ-sf and the MVPA recorded with
SWA, analyses revealed a 366 % higher MVPA level re-
ported on the IPAQ-sf compared to SWA (p = 0.001)
(Table 2). After excluding walking from the analysis, the
IPAQ-sf still reported statistically significant higher levels
of MVPA; 112 % higher compared to the SWA (p = 0.007).
When time in the different intensity categories were
analyzed separately, IPAQ-sf reported significantly more
time spent in MPA (602 min.wk−1, p = 0.001) and VPA
(60 min.wk−1, p = 0.001) compared to SWA; 342 % and
1200 % more, respectively. Stratified analyses on mean dif-
ferences between patients undergoing curative vs. palliative
chemotherapy revealed no significant difference between
the groups in over-report of MVPA (733 (443, 1023) vs.
521 (211, 832) min.wk−1, respectively, p = 0.395).
Accommodation of PA guidelines
Participants were categorized into fulfilling the American
Cancer Society PA guidelines of ≥150 min.wk−1 or not
when comparing MVPA obtained from the IPAQ-sf vs. the
SWA. Analyses revealed significant differences between
the IPAQ-sf and the SWA when walking was included to
the MVPA; IPAQ-sf identified 58 of the participants as
meeting the PA guidelines vs. 32 by SWA (p = 0.001). After
excluding walking from the analyses, 35 of the participants
self-reported accommodating the PA guidelines (p = 0.532).
Fig. 1 Bland-Altman plots depicting the mean differences (IPAQ-sf minus SenseWear Armband) for minutes spent in a Moderate-to-Vigorous
intensity Physical Activity (MVPA) including walking, b MVPA excluding walking, c Moderate intensity PA (MPA) including walking and d MPA
excluding walking. The solid line represents the mean, and the dashed lines represent the 1.96 SDs of the observations
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Discussion
In the present study, cancer patients participating in a
comprehensive lifestyle intervention while undergoing
chemotherapy over-reported time in MVPA compared
to SWA, when completing the IPAQ-sf. Specifically,
these cancer patients over-reported their moderate-to-
vigorous PA by nearly 100 min.day−1. No differences in
over-reporting were observed between patients undergo-
ing chemotherapy with curative or palliative intent.
Almost 90 % of the participants in the present study
perceived themselves as meeting the PA guidelines of
150 min.wk−1 of MPA while less than 50 % actually met
the PA guidelines according to the objective measures.
Our findings are supported by previous studies, where
more than half of healthy adults included perceived
themselves as accommodating the PA guidelines [24, 25].
Objective measures in the same population revealed that
only 15 % were reaching the guidelines [26]. The higher
percentage of participants self-reporting accommodating
the PA recommendations observed in the present study
compared to previous studies [26] may be a result from
drawing our participants from a lifestyle intervention fo-
cusing on the participants’ diet, mental stress and smoking
cessation in addition to their PA. In addition to measuring
the participants’ lifestyle behaviors, participants also re-
ceived recommendations on how to maintain or adhere to
a healthy lifestyle during their cancer treatment. It is a
well-known phenomenon that individuals participating in
a study often improve aspects of their behavior as a re-
sponse to being studied or they believe they have im-
proved more than what they actually have (the Hawthorne
effect) [27–29]. In the present study, the IPAQ-sf identi-
fied significantly more participants as accommodating the
PA guidelines of 150 min.wk−1 of MVPA vs. the SWA. Six
of the participants reported from 420 to 840 min.wk−1 of
MVPA, while less than 60 min.wk−1was registered on their
SWA. These findings are not only statistical significant,
but also of great clinical importance. Health care profes-
sionals should take these findings into consideration when
delivering PA recommendations in this population and if
using IPAQ-sf as an assessment tool in the clinic. In terms
of this knowledge, individualized PA recommendations
can be delivered with barriers such as fatigue, feeling sick,
loss of interest and nausea, in mind [13, 30], so that cancer
patients undergoing oncologic treatment can harvest the
known health benefits from adhering to the developed PA
guidelines [6].
Participants in the present validation study self-reported
being in MVPA 662 min.wk−1 more than what was object-
ively registered by the SWA; an over-reporting that is sup-
ported in the literature [9, 31–33]. Of the 844 min.wk−1
MVPA reported on the IPAQ-sf in the present study,
participants reported 459 min.wk−1 as walking activities.
As reported previously, IPAQ-sf may over-report MPA be-
cause it includes walking at any intensity [33]. In the
present study, IPAQ-sf over-reported time spent on
walking by 283 min.wk−1 or 1.6 times compared to MPA
obtained by the SWA. When including MPA from the
IPAQ-sf in the analysis, IPAQ-sf over-reported walking by
602 min.wk−1 or 3.4 times compared to MPA data on the
SWA. To include time spent on walking in the MVPA but
not differentiate the intensity of the walking may be a po-
tential source of over-reporting in cancer patients under-
going chemotherapy, and time spent on walking was thus
both included and excluded to MVPA in the present
study. A significant amount of the walking performed by
these patients may be objectively registered as light inten-
sity [34], while being experienced and self-reported as
moderate [35]. The IPAQ-sf defines MPA as activities that
make you breathe somewhat harder than normal [17].
Importantly, cancer patients dealing with disease- and
treatment-related side-effects such as reduced physical
capacity, fatigue, pain, depression and anxiety [36–39]
may feel short of breath at a much lighter intensity than
they have previously or compared to the population which
the questionnaire is developed for. Consequently, the ex-
perienced side-effects are a great source of over-reporting
since the patients might experience and report the PA as
moderate, while the SWA assesses the PA as light inten-
sity. This is important to have in mind when using self-
reports in cancer patients; many PA self-reports, like the
IPAQ-sf, are developed for use in a healthy population.
Gil-Rey et al. [39] thus suggest cancer-specific PA guide-
lines to maximize the health benefits in this population.
The participants did not systematically over-report
their PA levels when completing the IPAQ-sf; in other
words, higher physical activity levels from the SWA was
not associated with more over-reporting of MVPA re-
ported from the IPAQ-sf. Our findings are in contrast to
the findings of Johnson-Kozlow et al. [31], who revealed
Table 2 Mean difference and 95 % Confidence Intervals (95 % CI)
for PA obtained by the IPAQ-sf and SenseWear Armband
data (n = 66)





- Walking included 602 (390, 815) .001
- Walking excluded 143 (16, 269) .107
- Walking vs. Moderate
(IPAQ-sf vs. SWA)
283 (145, 421) .001
Vigorous PAa 60 (28, 94) .001
Moderate-to-Vigorous PA
- Walking included 662 (447, 878) .001
- Walking excluded 203 (69, 337) .007
aMissing values
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larger over-reporting in the breast cancer survivors who
reported the highest PA levels on the long form of the
IPAQ. Reasons for our conflicting findings may be the use
of different accelerometer in the two studies and the use
of the long versus the short form of the IPAQ in the
study of Johnson-Kozlow and colleagues [31] and the
present study, respectively. The long form of the IPAQ
gives a total of 35 examples of PA across different activity
domains, i.e. recreational sports, leisure time and house-
work PA. This provides many opportunities for “forward
telescoping”; a recall bias occurring if the activities were
recalled as taking place during the same seven-day period
which is monitored, but actually took place previously
[40]. Secondly, while the participants were undergoing
chemotherapy in the present study and may not have been
able to perform much vigorous PA, the participants in the
study of Johnson-Kozlow et al. [31] were cancer survivors
two years post diagnosis. Recall of vigorous PA is more
likely to be subject to “forward telescoping” on PA self-
reports, since these activities are often easier to remember
due to strong, distinct physiological signals [40].
Importantly, IPAQ has been criticized for being com-
plicated to complete [41] due to difficulties in remem-
bering which activities they performed the past seven
days, to distinguish the intensity of the different
activities and last but not least trying to identify whether
or not the activities lasted ≥ 10 min [42]. These aspects
may be even harder to recognize for cancer patients ex-
periencing disease- and treatment-related side effects
such as pain, mental stress, cognitive difficulties and
fatigue [13, 14, 37]. When comparing the IPAQ-sf to the
SWA, activities lasting ≥ 10 min from the SWA was ap-
plied in the analyses, which may lead to great over-
reporting if the activity lasted < 10 min. Thus, post hoc
PA comparisons assessed by the IPAQ-sf and minute-
by-minute SWA data were conducted in the present
study (data not shown). Analyses revealed that IPAQ-sf
still significantly over-reported VPA but IPAQ-sf now
significantly under-reported MPA by 44 % compared to
the SWA. The difficulties in completing the IPAQ-sf are
reasonably clear. Importantly, there are currently no
gold-standard for quantifying PA [43]; however, acceler-
ometers are a precise and valid tool and thus commonly
used in validating self-reports of PA [32]. Consequently,
it is of concern that both the evidence regarding PA in
cancer patients and the PA recommendations in this
population is developed on the basis of self-reported PA
data, which in turn has impact on the validity of those
recommendations [6]. Another question that arises in
this context is why self-reports only addresses PA in
bouts >10 min, when there is rapidly growing evidence
on health benefits in shorter bouts of PA [44, 45]. This is;
however, an unexplored field in cancer patients, which
needs further investigation, especially since activities of
longer duration may be hard to complete for cancer pa-
tients with impaired physical capacity due to the oncologic
treatment.
There are strengths and limitations of the present
study. To our knowledge, this is the first time the IPAQ-
sf has been compared to an objective PA monitor in
cancer patients undergoing chemotherapy with either
curative or palliative intent. One key aspect when
designing the present study was to make the objective
registrations feasible to the patients. Many different
guidelines regarding days wearing the activity monitors
are previously provided, with a minimum wearing time
of four days recommended [46, 47]. One weakness of
the present study is that only 66 % of the eligible pa-
tients were included, despite wearing the SWA for only
five days, due to voluntary dropout, SWA malfunction
or insufficient wearing time, leading to a higher inclu-
sion of breast cancer patients who were either married
or living together with someone compared to the total
sample. These observations may indicate that a shorter
wearing time is preferred in this population with regard
to feasibility. Secondly, the participants were instructed
to remove the SWA during water-based activities and
activities such as swimming were thus not recorded.
However, cancer patients at our clinic were advised to
refrain from activities such as swimming in public pools
due to reduced immune function and increased infection
risk during chemotherapy. Further, the present study, as
previous lifestyle interventions, is limited by including
the healthier and fitter participants compared to the
population from which they are drawn [19, 30]. Un-
fortunately, no Bland-Altman plot was calculated for
VPA since only three of the participants had bouts
of ≥10 min of VPA recorded on the SWA. Further, the
present study is limited by the amount of questions asked.
The present validation study was part of a comprehensive
lifestyle intervention, which focused on the participants'
diet, mental stress, smoking cessation and quality of life in
addition to their PA level. The large amount of questions
asked, perhaps in combination with side effects from the
disease and its treatment, may have affected the accuracy
of the participants’ answers.
Conclusion
Based on our findings, cancer patients participating in a
lifestyle intervention while undergoing chemotherapy
grossly over-report their PA level from the past seven
days when using the IPAQ-sf. Thus, the IPAQ-sf seems
to be insufficient when assessing PA level in cancer pa-
tients undergoing oncologic treatment. Activity monitors
or other objective tools should be considered in this
population as an attempt to bridge the gap between how
physical active the cancer patients perceive themselves
and how physical active they actually are, in order to
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provide each patient with correct and individualized PA
recommendations.
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